Skip to main content
Sanofi's Admelog approved by FDA as follow-on biologic of Lilly's Humalog

The FDA approved Sanofi's Admelog, or insulin lispro injection, as a treatment for adults with type 1 and type 2 diabetes and children with type 1 diabetes. Admelog has been approved as the first follow-on biologic version of Humalog, Eli Lilly and Co.'s fast-acting insulin.

Full Story: